| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lite Strategy, Inc.$0.98
+0.01 (+0.69%)
D 24Pipeline Score Richly Valued Pharma · Clinical
Market Cap
36.41 M
EPS
-2.01
P/E Ratio
-
Value Trade
553.57 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
30.00 K
Total Assets
57.79 M
Total Liabilities
952.00 K
Equity
56.84 M
D/E Ratio
12,345
-8.55 %
Week
-7.76 %
1 Month
-4.46 %
3 Month
-36.69 %
6 Month
-99.91 %
5 Year
-100 %
All Time
Cash Data
Cash Position
7.54 M
Monthly Burn
7.20 M
Runway
0 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
191.84 K
52 Week Range
0.95 - 9
% held by Insiders
12.18 %
% held by Institutions
17.31 %
Enterprise Value
28.86 M
Total Shares
36.35 M
Short %
0.33 %
Float Shares
31.66 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lite Strategy, Inc.
251Total events
2Upcoming
61Tier-1 (high impact)
2005 – 2026Coverage
Upcoming catalysts 2
Event history 249
Jun 22, 2026
◆Oral PresentationPresentation
Lite Strategy to attend panel at Litecoin Foundation Summit in Amsterdam
Jul 18, 2025
▼Equity OfferingCorporate
MEI Pharma announces $100M private placement (PIPE) to fund Litecoin treasury strategy
May 13, 2025
●Quarterly UpdateCorporate
MEI Pharma reports Q3 fiscal year 2025 cash position and ongoing strategic alternatives evaluation
May 13, 2025
◆Pipeline PrioritizationCorporate
Evaluation of strategic alternatives ongoing, including out-licensing and M&A
May 13, 2025
▼Restructuring LayoffsCorporate
Reduction-in-force progressing in stages as strategic direction evolves
Q2 2025
●Runway Guidance UpdateCorporate
Projected cash balance of ~$100M to fund operations through mid-2025
Feb 12, 2025
●Quarterly UpdateCorporate
MEI Pharma reports Q2 fiscal 2025 cash position and ongoing strategic review
Jan 2025
▼Restructuring LayoffsCorporate
MEI Pharma commences cash preservation efforts including reduction-in-force
Drug Pipeline Intelligence
D24
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.0x
rNPV / MCap Top 22%
Micro Cap (rank 708 of 906)
Percentile RankLite Strategy, Inc. faces pipeline headwinds (24/100), with $652M risk-adjusted pipeline value, led by Phenoxodiol in Prostate Cancer (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| phenoxodiol Small molecule | Fallopian Tube Cancer | Phase 3 | NCT00091377 | 42% | $557M | COMPLETED | 207 | - | - | Mar 1, 2008 | - | Jul 14, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
voruciclib | acute myeloid leukemia and B-cell malignancies | Phase 1 | 2023-12-11 | favorable safety profile; no observed overlapping toxicities; meaningful anti-tumor activity; 40 patients enrolled; median age 75 years (range 63-80) Read More | inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the pa Read More | |
voruciclib | acute myeloid leukemia and B-cell malignancies | Phase 1 | 2023-12-11 | favorable safety profile; no observed overlapping toxicities; meaningful anti-tumor activity; 40 patients enrolled; median age 75 years (range 63-80) Read More | inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the pa Read More | |
voruciclib | acute myeloid leukemia and B-cell malignancies | Phase 1 | 2023-12-11 | favorable safety profile; no observed overlapping toxicities; meaningful anti-tumor activity; 40 patients enrolled; median age 75 years (range 63-80) Read More | inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the pa Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LITS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LITS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LITSLite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam
Lite Strategy, Inc. will participate in the Litecoin Foundation Summit on June 22-23, 2026, in Amsterdam. This marks the first appearance of a NASDAQ-listed digital asset treasury company at the event, showcasing the institutional adoption of Litecoin. The panel will feature key figures from Lite Strategy and the Litecoin Foundation, discussing the future of Litecoin as a reserve asset.
Read more →LITSLite Strategy Leads Strategic Investment in LitVM
Lite Strategy, Inc. has closed a $1.0 million strategic investment in ZK Innovations Inc., the developer of LitVM, a zero-knowledge Layer 2 platform for Litecoin. This investment aims to enhance Litecoin's functionality, enabling decentralized finance and smart contracts. Lite Strategy's CEO emphasized the importance of building infrastructure to create shareholder value. The investment aligns with the upcoming launch of LitVM's mainnet, which will introduce new capabilities to the Litecoin ecosystem.
Read more →LITSLite Strategy Reports Fiscal 2026 Third Quarter Results
Lite Strategy, Inc. reported its fiscal 2026 third quarter results, highlighting successful treasury management and a robust covered call option program. The company generated $0.7 million in net proceeds and repurchased over 1.6 million shares. CEO Jay File emphasized the focus on generating yield from Litecoin holdings while enhancing shareholder value. The SEC's recent guidance classifying Litecoin as a digital commodity is seen as a positive development for the company and the broader Litecoin ecosystem.
Read more →LITSLite Strategy Reports Fiscal 2026 Second Quarter Results
Lite Strategy, Inc. reported its fiscal 2026 second quarter results, highlighting a strategic shift to actively manage its Litecoin (LTC) holdings. The company generated significant revenue through covered call options and initiated a $25 million stock repurchase program. Management aims to differentiate itself from passive digital asset vehicles by enhancing shareholder value and supporting the Litecoin ecosystem.
Read more →LITSLite Strategy Announces $25M Share Repurchase Program, Signalling Shift From Initial Litecoin Accumulation to Active Capital Market Operations LITS Board of Directors Reaffirms Commitment to Driving Long-Term Stockholder
Lite Strategy, Inc. (LITS) announced a $25 million share repurchase program, indicating a strategic shift from accumulating Litecoin to engaging in active capital market operations. The Board of Directors aims to enhance stockholder value through this initiative, which allows for the repurchase of shares based on market conditions. The company may also implement a Rule 10b5-1 trading plan to facilitate these purchases. However, potential risks include challenges in executing the repurchase effectively and fluctuations in the value of Litecoin impacting operations.
Read more →LITSLite Strategy, Inc. (NASDAQ: LITS) is the first U.S.-listed public company to adopt Litecoin as its primary reserve asset. Formerly MEI Pharma, the Company has expanded its business model beyond its portfolio of drug can
Lite Strategy, Inc., formerly MEI Pharma, has rebranded to highlight its focus on adopting Litecoin as its primary reserve asset. The company has secured over $100 million in Litecoin and aims to pioneer digital asset treasury management. Alongside the rebranding, Lite Strategy continues to evaluate its drug development pipeline, suggesting a blend of innovative digital strategies with traditional biotechnology initiatives. The partnership with LTC creator Charlie Lee and GSR Ventures is expected to strengthen its market approach.
Read more →LITSMEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising SAN DIEGO, 5 August 2025 – MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or “the
MEI Pharma, Inc. announced its acquisition of 929,548 Litecoin tokens as part of a $100 million institutional treasury strategy, making it the first U.S.-listed public company to adopt Litecoin as a reserve asset. This initiative is in partnership with GSR and guided by Litecoin founder Charlie Lee, emphasizing the scalability and reliability of Litecoin for treasury purposes. In addition to this strategic step, MEI Pharma is also planning further development in its drug candidate pipeline.
Read more →LITSMEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange Charlie Lee, the Founder of Litecoin and a lead invest
MEI Pharma recently announced a $100 million private placement aimed at initiating a Litecoin treasury strategy, making it the first publicly traded company to adopt Litecoin as a treasury reserve asset. The transaction will appoint Litecoin’s founder, Charlie Lee, to its Board of Directors and engage GSR as a digital asset advisor. This strategy reflects a significant shift toward integrating cryptocurrency into corporate financial practices, with expectations for broader adoption in traditional capital markets. The company aims to bolster its cash management framework through the holding of LTC.
Read more →LITSMEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position Evaluation of Strategic Alternatives is Ongoing SAN DIEGO--(BUSINESS WIRE) —
MEI Pharma reported its third quarter results for fiscal year 2025, indicating a cash position of $20.5 million and no debt. The company is actively evaluating strategic alternatives, including potential out-licensing and M&A opportunities, with the aim of maximizing asset value for shareholders. However, there is uncertainty surrounding the success of these strategies and a reduction in workforce is being implemented, which may affect operational capabilities.
Read more →LITSMEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position Evaluation of Strategic Alternatives is Ongoing SAN DIEGO--(BUSINESS WIRE) —
MEI Pharma reported its financial results for the second quarter of fiscal year 2025, revealing a cash position of $23.7 million. The company is actively exploring strategic alternatives, including potential mergers or out-licensing opportunities, to enhance the value of its assets. However, the evaluation process carries risks, and there is no assurance that it will result in successful transactions. Furthermore, MEI Pharma has initiated workforce reductions as part of its cash preservation efforts amid continued operational and financial challenges.
Read more →LITSMEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position Reaffirms Continuation of Evaluation of Strategic Alternatives SAN DIEGO--(BUSINESS WIRE) —
MEI Pharma reported its first-quarter results for fiscal year 2025, indicating a cash position of $26.9 million without any debt. The company confirmed its ongoing evaluation of strategic alternatives to maximize asset value, involving potential out-licensing and merger opportunities. However, they have commenced cash preservation efforts including staff reductions that will occur in stages. The press release highlighted uncertainties about the success of these strategies and warned stakeholders of various risks that may affect potential agreements.
Read more →LITSMEI Pharma Reports Fiscal Year End 2024 Cash Position Confirms Continuation of Evaluation of Strategic Alternatives SAN DIEGO--(BUSINESS WIRE) —
MEI Pharma, Inc. has reported its financial results for the fiscal year ending June 30, 2024. The company is evaluating strategic alternatives to enhance the value of its assets for shareholders, including potential mergers and acquisitions. To conserve its cash, MEI has initiated workforce reductions and stopped the clinical development of its drug voruciclib. As of the end of the fiscal year, the company holds $38.3 million in cash and equivalents, with rising concerns regarding the success of its strategic evaluations.
Read more →LITSVoruciclib: An Oral CDK9 Inhibitor for AML and Other Malignancies July 2024 Forward Looking Statements Certain information contained in this communication that are not historical in nature are forward-looking statements
The article discusses Voruciclib, an oral CDK9 inhibitor targeted at acute myeloid leukemia (AML) and other malignancies. Currently in clinical development, it is being evaluated in combination with Venetoclax, showing promise for patients who have not responded to initial therapies. The ongoing trials aim to demonstrate its safety and efficacy, with expected data readouts in late 2024 and early 2025. The article highlights both the potential benefits and inherent risks associated with the commercialization and clinical success of Voruciclib.
Read more →LITSMEI Pharma to Consider Strategic Alternatives Company Commences a Cash Preservation Plan Including a Reduction in Force SAN DIEGO--(BUSINESS WIRE)—
MEI Pharma has announced a cash preservation plan involving a workforce reduction and the cessation of its clinical development activities for voruciclib. The company's Board of Directors is exploring strategic alternatives, which may include asset sales or an orderly wind down if no viable options are identified. Leadership changes accompany this process, with key executives transitioning out, and the company intends to focus on prudent cash management during this evaluation period. Stakeholders are cautioned that the ongoing review poses significant risks to the company's future operations.
Read more →LITSNASDAQ: MEIP Corporate Overview Novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies
NASDAQ: MEIP provides an overview of its two novel drug candidates aimed at overcoming resistance mechanisms to current cancer therapies. Voruciclib, an oral CDK9 inhibitor, and ME-344, an OXPHOS inhibitor, are being evaluated in combination with existing therapies for conditions such as acute myeloid leukemia and HER2-negative breast cancer. The company is preparing for further clinical development, with sufficient cash reserves to continue operations for at least the next year. However, various risks associated with FDA approvals and market acceptance remain significant factors to consider moving forward.
Read more →LITSMEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights -- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Antic
MEI Pharma reported encouraging updates in its third quarter fiscal results, highlighting the ongoing Phase 1 study of voruciclib in combination with venetoclax, which has shown anti-leukemic activity and no overlapping toxicity. The company is focused on advancing this program amid its financial standing of $56.6 million in cash. However, it faces challenges, such as no revenue for the recent quarter and ongoing clinical expenses. The board remains aligned on prioritizing the development of voruciclib and a new formulation of ME-344.
Read more →LITSMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights SAN DIEGO –
MEI Pharma reported its financial and operational results for the second quarter of fiscal year 2024, noting significant progress in clinical studies for its drug candidates voruciclib and ME-344. The company is on track for preliminary data readouts expected in the first half of 2024. Despite positive advancements in clinical trials, MEI reported no revenue for the quarter and a higher cash burn compared to the previous year. The firm maintains a strong cash position from its assets, sufficient to support operations over the next 12 months.
Read more →LITSinability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the pa
MEI Pharma presented clinical data on voruciclib, a CDK9 inhibitor, at the ASH2023 conference. The data showed a favorable safety profile for voruciclib both as a monotherapy and in combination with venetoclax for treating acute myeloid leukemia and B-cell malignancies. There were no observed overlapping toxicities between the two treatments, and preliminary results indicated meaningful anti-tumor activity. The ongoing study aims to further evaluate the efficacy and safety of this combination therapy.
Read more →LITSMEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights SAN DIEGO –
MEI Pharma has reported its financial results and operational highlights for the first quarter of fiscal year 2024. The company noted strong support for ongoing clinical trials, particularly for its CDK9 inhibitor voruciclib and its mitochondrial inhibitor ME-344. Revenue increased significantly, largely due to the conclusion of a commercialization agreement, and the company reported a net income compared to a loss in the same quarter last year. Looking ahead, MEI expects to announce key clinical trial data in early to mid-2024 but faces operational challenges and market risks.
Read more →LITSMEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital Commits to Capital Return of Up to $3.15 per Share Adds Three New Directors and Forms Capital Allocation Committee of the Board SAN DIEGO, TORONTO a
MEI Pharma has entered into a cooperation agreement with Anson Funds and Cable Car Capital, allowing for a potential capital return of up to $3.15 per share. The agreement also involves the addition of three new independent directors and the formation of a Capital Allocation Committee. This move aims to enhance stockholder engagement while the company focuses on advancing its two key cancer therapy programs, voruciclib and ME-344. Key clinical trial outcomes will significantly influence the company's approach going forward.
Read more →LITSMEI Pharma Adopts Limited-Duration Stockholder Rights Plan - Responds to Substantial Stock Accumulation by Anson Advisors and Cable Car Capital - - Protects Long-Term Value of All Stockholders Investments in MEI Pharma -
MEI Pharma, Inc. has established a limited-duration stockholder rights plan in response to significant stock accumulation by Anson Advisors and Cable Car Capital. The Board aims to protect the long-term value of all stockholders' investments and prevent hostile control scenarios. As part of this initiative, stockholders will receive rights to acquire preferred stock under specific conditions, reinforcing the company's commitment to optimizing stockholder returns amidst ongoing drug development efforts expected to yield results in early 2024.
Read more →LITSMEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights Conference Call Today at 5:00 p.m. Eastern Time
MEI Pharma has reported its financial results for the fiscal year 2023, highlighting ongoing clinical trials for its drug candidates voruciclib and ME-344. The company anticipates data readouts from these trials, which are expected to support further development of therapies for acute myeloid leukemia and colorectal cancer. MEI Pharma's cash balance is described as sufficient to fund operations for at least the next 12 months, reinforcing their commitment to developing cancer therapies despite inherent risks in the industry.
Read more →LITSMEI Pharma Announces Results of Special Meeting of Stockholders
MEI Pharma announced the results of its Special Meeting of Stockholders, where a proposed merger with Infinity Pharmaceuticals was not approved. With only 47.86% of shares voting in favor, MEI has sent a notice terminating the agreement. Despite this setback, the company remains focused on its development pipeline, with upcoming clinical data from Voruciclib and ME-344 expected around year-end. Management aims to capitalize on existing opportunities to create stockholder value moving forward.
Read more →LITSMEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
MEI Pharma is encouraging shareholders to vote in favor of its pending transaction with Infinity Pharmaceuticals ahead of a special meeting set for July 23, 2023. The company highlights the potential benefits of the merger, including access to a well-capitalized entity with promising therapeutic development pipelines. Independent proxy advisory firms have also recommended that shareholders support the transaction. The upcoming data releases related to this merger may provide added potential for value creation.
Read more →LITSMEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
MEI Pharma is actively encouraging its shareholders to vote in favor of merging with Infinity Pharmaceuticals during the special meeting scheduled for July 23, 2023. The merger aims to create a combined entity that is better positioned to advance a diverse pipeline of clinical-stage therapies. Leading proxy advisory firms support this transaction, emphasizing its strategic benefits. However, there are risks associated with the merger, including uncertainties surrounding regulatory approvals and potential unforeseen costs.
Read more →LITSMEI Pharma Postpones Special Meeting of Shareholders
MEI Pharma has announced a postponement of its special meeting of shareholders regarding the proposed merger with Infinity Pharmaceuticals. The new meeting date is set for July 23, 2023, giving shareholders additional time to consider the transaction, which has received positive endorsements from proxy advisory firms ISS and Glass Lewis. The merger is viewed as strategically beneficial, positioning the combined company to advance a diversified pipeline of clinical-stage development programs. However, the delay raises concerns about the timing and completion of the merger.
Read more →LITSMEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals Glass Lewis Joins ISS in Recommending that MEI Shareholders Vote FOR the Infinity Transaction
MEI Pharma has urged its shareholders to vote in favor of its proposed merger with Infinity Pharmaceuticals, set for discussion at a special meeting on July 14, 2023. Recommendations from proxy advisory firms ISS and Glass Lewis strongly support this transaction, indicating a thorough strategic review process and a compelling rationale behind the merger. The combined company is expected to leverage its resources for advancing a diversified clinical-stage pipeline aimed at addressing unmet medical needs.
Read more →LITSMEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote FOR Pending Transaction with Infinity Pharmaceuticals Affirms Value Creating Potential of Proposed Transaction with Infinity Pha
MEI Pharma has announced that Institutional Shareholder Services (ISS), a notable proxy advisory firm, has recommended that shareholders vote in favor of the company's pending transaction with Infinity Pharmaceuticals. This endorsement indicates confidence in the merger's potential to generate significant value for stakeholders. MEI Pharma emphasizes that the merger would lead to a well-capitalized combined entity with a diversified clinical-stage pipeline, thereby enhancing opportunities for both shareholders and patients. Shareholders are encouraged to participate in the vote scheduled for July 14, 2023.
Read more →LITSMEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Comb
MEI Pharma has communicated to its shareholders the value-creating potential of its proposed merger with Infinity Pharmaceuticals. The company is urging investors to vote in favor of the transaction, highlighting the promising clinical pipeline that includes drugs like voruciclib and ME-344, aimed at treating acute myeloid leukemia and colorectal cancer. The board believes the merger will strengthen the company's position in cancer care and enhance options for patients. The special meeting for shareholder voting is scheduled for July 14, 2023.
Read more →LITSMEI Pharma Responds to Anson and Cable Car
MEI Pharma has formally responded to Anson Advisors and Cable Car Capital, reiterating their rejection of a non-binding acquisition proposal. The company's Board believes that the proposal does not benefit shareholders and is an attempt to acquire the Company unduly. MEI Pharma is committed to ensuring that shareholders benefit from its ongoing programs and maintains its focus on finalizing its merger with Infinity Pharmaceuticals. The company encourages its shareholders to disregard misleading statements from the proposing entities.
Read more →LITSMEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates Event Available at 8:00 a.m. Eastern Time on
MEI Pharma and Infinity Pharmaceuticals are hosting a video webcast on June 19, 2023, to provide an update on their pending merger. The merger aims to consolidate their resources and expertise to develop three promising clinical-stage oncology drug candidates. During the webcast, executive management will present details about the merger and its potential impact on patient outcomes, featuring discussions with recognized experts in cancer treatment. The merger proposal is still subject to regulatory approvals and potential delays.
Read more →LITSMEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor
MEI Pharma announced the planned departure of Chief Financial Officer Brian Drazba, effective by September 1, 2023, and the appointment of Justin File as his successor. Justin File, who joined the company on June 12, 2023, has 30 years of experience and a strong background in finance within the life sciences sector. The transition is part of MEI's succession planning, aiming to maintain stability as the company advances its oncology pipeline and prepares for upcoming data readouts. Grants for inducement stock options were also announced for the new CFO, emphasizing the company's commitment to leadership continuity and strategy execution.
Read more →LITSMEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
MEI Pharma has announced the planned departure of CEO Daniel P. Gold, Ph.D., effective June 2, 2023, as part of a succession plan. David M. Urso, who joined the company in 2014 and has served as COO since 2018, will take over as CEO and also join the board of directors. Dr. Gold will remain involved by serving on the board, bringing his experience to the ongoing leadership transition. This change comes as MEI Pharma continues to advance its pipeline of cancer therapies.
Read more →LITSMEI Pharma Board of Directors Rejects Unsolicited Proposal
MEI Pharma's Board of Directors has rejected an unsolicited proposal from Anson Advisors Inc. and Cable Car Capital LLC to acquire the company for a minimum of $8.00 per share. The Board determined that the proposal undervalued MEI Pharma and was not superior to the already proposed transaction with Infinity Pharmaceuticals, which is still moving forward. Shareholders have been advised that no action is required on their part at this time.
Read more →LITSMEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
MEI Pharma has confirmed receiving an unsolicited acquisition proposal to buy all outstanding shares for at least $8.00 each. This proposal is from Anson Advisors Inc. and Cable Car Capital LLC and also includes a contingent value right linked to the company's clinical assets. The MEI Board is reviewing the proposal with its financial and legal advisors while continuing its commitment to a pending merger with Infinity Pharmaceuticals. Shareholders are advised that no immediate action is required.
Read more →LITSMEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights MEI Begins Fourth Fiscal Quarter with $112.0 Million in Cash
MEI Pharma, Inc. reported its third quarter financial results for fiscal year 2023, showing a cash balance of $112 million that will support operations for at least two years. The company highlighted its clinical-stage pipeline progress, particularly with voruciclib and ME-344, as it anticipates data releases by the end of the year. However, the recent decision by Kyowa Kirin to halt development of zandelisib indicates some partnership challenges. MEI is also exploring a merger with Infinity Pharmaceuticals to potentially enhance its market position.
Read more →LITSMEI PHARMA ANNOUNCES 1-FOR-20
MEI Pharma, Inc. has announced a 1-for-20 reverse stock split, effective April 17, 2023, to comply with Nasdaq's minimum bid price requirements. This move was approved by stockholders on January 5, 2023, and is expected to increase the per-share trading price of the company's common stock. Following the split, the number of outstanding shares will be reduced significantly. Stockholders holding shares electronically will not need to take further action, while those with physical certificates will receive instructions for exchange.
Read more →LITSMEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates Combination will create a company with a diverse product development pipeline led by a
MEI Pharma and Infinity Pharmaceuticals have entered into a definitive merger agreement to enhance their oncology drug development efforts. This all-stock transaction will combine their resources to advance three clinical-stage oncology candidates, including eganelisib, which has shown clinical activity in over 350 patients. The merged entity is expected to have approximately $100 million in capital, funding operations until mid-2025 and facilitating ongoing clinical studies. The merger has been approved by both companies' boards and is pending shareholder approvals.
Read more →LITSMEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights MEI Begins Third Fiscal Quarter with $124 Million in Cash
MEI Pharma, Inc. reported its financial results for the second quarter of the fiscal year 2023, highlighting a cash position of $124 million. The company anticipates key clinical readouts for its oncology drug candidates, voruciclib and ME-344, by the end of the calendar year. These developments promise to inform future plans within the oncology sector, particularly concerning CDK9 inhibition and mitochondrial inhibition. MEI Pharma's solid cash reserves ensure they can continue their operations and development plans over the next two years.
Read more →LITSMEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting SAN DIEGO and TOKYO, December 5 and 6, 2022 MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical co
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting SAN DIEGO and TOKYO, December 5 and 6, 2022 MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and
Read more →LITSMEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights MEI Begins Second Fiscal Quarter with $138 Million in Cash
MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights MEI Begins Second Fiscal Quarter with $138 Million in Cash SAN DIEGO November 14, 2022 MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies f
Read more →LITSMEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights MEI Begins Fourth Fiscal Quarter with $169.0 Million in Cash
MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights MEI Begins Fourth Fiscal Quarter with $169.0 Million in Cash SAN DIEGO May 23, 2022 MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for
Read more →LITSMEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA MEI to Host Zandelisib Program Update Webcast Today at 4:30 p.m. Eastern Time SAN DIEGO and TOKYO, Japan March 24 and 25,
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA MEI to Host Zandelisib Program Update Webcast Today at 4:30 p.m. Eastern Time SAN DIEGO and TOKYO, Japan March 24 and 25, 2022 MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co.,
Read more →LITSMEI Pharma Announces Pricing of Public Offering of Common Stock San Diego
MEI Pharma Announces Pricing of Public Offering of Common Stock San Diego December 1, 2021 MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has priced the underwritten public offering of
Read more →LITSMEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma Zandelisib Demonstrated 70.3% Objec
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response 9.9
Read more →LITSMEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors
MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors SAN DIEGO, November 23, 2021 MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Mr. Sujay Kango
Read more →LITSMEI Pharma Announces Planned Chief Financial Officer Transition Brian Drazba, Chief Financial Officer of MEI Pharma, to Retire at the End of 2021
MEI Pharma Announces Planned Chief Financial Officer Transition Brian Drazba, Chief Financial Officer of MEI Pharma, to Retire at the End of 2021 SAN DIEGO, August 5, 2021 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies fo
Read more →LITSForward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are "forward-looking statements" within the meaning of the safe harbor provisions of
Post-ASCO 2021 Investor & Analyst Event: Zandelisib in Focus NASDAQ: MEIP June 10, 2021 Exhibit 99.1 Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are "forward-looking statements" within
Read more →LITSMEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer
MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer SAN DIEGO, April 30, 2021 MEI Pharma, Inc. (NASDAQ: MEIP) ( MEI ), a late-stage pharmaceutical company focused on advancing new therapies for cance
Read more →LITSHelsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis Lugano, Switzerland and San Diego, USA
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis Lugano, Switzerland and San Diego, USA, July 2, 2020 Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, an
Read more →LITSMEI Pharma Appoints Cheryl Cohen, Product Launch and Commercialization Veteran, to its Board of Directors
MEI Pharma Appoints Cheryl Cohen, Product Launch and Commercialization Veteran, to its Board of Directors SAN DIEGO, April 14, 2020 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced the
Read more →LITSMEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401 MEI Pharma and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S.; MEI to book U.S. sales on 50-50 pro
MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401 SAN DIEGO, and TOKYO, April 14, 2020 MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today jointly announced that the companies have ent
Read more →LITSMEI Pharma Appoints Longtime Industry Consultant and Executive Tamar Howson to its Board of Directors
MEI Pharma Appoints Longtime Industry Consultant and Executive Tamar Howson to its Board of Directors July 3, 2019 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced the appointment of Ta
Read more →LITSMEI Pharma Presents Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Statistically signific
MEI Pharma Presents Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Statistically significant biologic anti-tumor activity demonstrated as measured
Read more →LITSMEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting December 1, 2018 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stag
Read more →LITSMEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan MEI to Receive $10 Million Upfront Payment, Plus Milestones and Tiered Royalty Payments SAN DIEGO, and TOKYO
MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan MEI to Receive $10 Million Upfront Payment, Plus Milestones and Tiered Royalty SAN DIEGO, and TOKYO, November 5, 2018 MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Hakko Kirin C
Read more →LITSMEI Pharma Promotes David M. Urso to Chief Operating Officer
MEI Pharma Promotes David M. Urso to Chief Operating Officer SAN DIEGO, July 16, 2018 MEI Pharma, Inc. (NASDAQ: MEIP) a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announce
Read more →LITSMEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 90% Objective Response Rate Observed in Patients
MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 90% Objective Response Rate Observed in Patients with Indolent B-Cell Malignancies SAN DIEGO, June 4, 20
Read more →LITSMEI Pharma Announces $75 Million Private Placement
MEI Pharma Announces $75 Million Private Placement SAN DIEGO, May 14, 2018 MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announced it enter
Read more →LITSMEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors
MEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors SAN DIEGO, February 26, 2018 MEI Pharma, Inc. (NASDAQ: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Frederick
Read more →LITSMEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor Clinical-Stage Asset in Validated Class of Drugs with Demonstrated Value Potent Inhibitor of CDK9
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor Clinical-Stage Asset in Validated Class of Drugs with Demonstrated Value Potent Inhibitor of CDK9, 4/6 & 1, Potential to Overcome Resistance to BCL-2 Inhi
Read more →LITSMEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer San Diego
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer San Diego, April 3, 2017 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Brian Drazba as Chief
Read more →LITSHelsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases MEI Pharma to receive $20 million
Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases MEI Pharma to receive $20 million in near-term cash payments, plus up to $444 million in p
Read more →LITSPete De Spain Vice President, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI Pharma Appoints Dr. Christine White as Chairman of the Board San Diego
MEI Pharma Appoints Dr. Christine White as Chairman of the Board San Diego December 10, 2015 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Christine White, MD, as Chairm
Read more →LITSAza + Pracinostat in AML: Introduction Elderly AML patients, deemed unsuitable for intensive therapy, have limited treatment options Pracinostat is a potent hydroxamic acid based oral HDAC inhibitor selective for class I
G Garcia-Manero1, E Atallah2, B Medeiros3, M Arellano4, SK Khaled5, M Patnaik MD6, O Odenike7, SH Sayar8, MK Tummala9, P Patel10, L Maness-Harris11, R Stuart12, E Traer13, K Karamlou14 and A Yacoub15 1 University of Texas MD Anderson Cancer Center, Houston, TX; 2Medical College
Read more →LITSPete De Spain Vice President, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI Pharma Reports Fiscal Year 2015 Results Company Begins New Fiscal Year with $63.8 Million and
MEI Pharma Reports Fiscal Year 2015 Results Company Begins New Fiscal Year with $63.8 Million and Three Drug Candidates in the Clinic San Diego September 2, 2015 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for can
Read more →LITSPete De Spain Vice President, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI Pharma Announces Top-Line Data from Randomized Phase II Clinical Study of Pracinostat in Fron
Contact: Pete De Spain Vice President, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI Pharma Announces Top-Line Data from Randomized Phase II Clinical Study of Pracinostat in Front-Line Myelodysplastic Syndrome Compan
Read more →LITSPete De Spain Vice President, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK San Diego
MEI PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK San Diego December 12, 2014 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering
Read more →LITSForward Looking Statements These slides and the accompanying oral presentation contain forward looking statements. Actual events or results may differ materially from those projected in any of such statements. Additional
Expect to unblind study and report topline data in March 2015 29 Phase II Front Line MDS Study (MEI 003) Patient Demographics Study MEI 003 (N=102) Pub (N=99) Pub (N=179) Age Median 65 65 70 yrs 29% 71% 69 yrs NR NR 69 yrs 32% 68% Gender Male Female 69% 31% 72% 27% 74% 26% PS 0 1
Read more →LITSPracinostat in Combination With Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients With Previously Untreated Acute Myeloid Leukemia Guillermo Garcia-Manero, MD 1 ; Ehab Atallah, MD 2 ; Olat
Figure 1. Study Design AML, acute myeloid leukemia; CR, complete response; CRi, complete response with incomplete blood count recovery; MLFS, morphologic leukemia-free state. Eligibility Criteria Table 1. Patient Disposition N=41 Number of Patients Active 25 Number of Pat
Read more →LITSPete De Spain Vice President, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA REPORTS FISCAL YEAR 2014 RESULTS San Diego
Contact: Pete De Spain Vice President, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA REPORTS FISCAL YEAR 2014 RESULTS San Diego September 9, 2014 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the c
Read more →LITSPete De Spain Vice President, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA COMPLETES ENROLLMENT IN RANDOMIZED PHASE II CLINICAL TRIAL OF PRACINOSTAT IN FRONT LIN
MEI PHARMA COMPLETES ENROLLMENT IN RANDOMIZED PHASE II CLINICAL TRIAL OF PRACINOSTAT IN FRONT LINE MYELODYSPLASTIC SYNDROME Data from Multi-Center, Placebo-Controlled Study Anticipated in Q1 2015 San Diego September 2, 2014 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company
Read more →LITSPete De Spain Vice President, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA ADDS FORMER VC DAVID URSO AS SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT AND GENERA
MEI PHARMA ADDS FORMER VC DAVID URSO AS SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT AND GENERAL COUNSEL San Diego April 8, 2014 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appoin
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK San Diego
MEI PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK San Diego October 25, 2013 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA S MITOCHONDRIAL INHIBITOR ME-344 SHOWS PRELIMINARY EVIDENCE OF SINGLE-AGENT ACTIVITY IN
MEI PHARMA S MITOCHONDRIAL INHIBITOR ME-344 SHOWS PRELIMINARY EVIDENCE OF SINGLE-AGENT ACTIVITY IN FIRST-IN-HUMAN CLINICAL STUDY Extension of Progression-Free Survival Observed Compared to Last Prior Therapy San Diego October 21, 2013 MEI Pharma, Inc. (Nasdaq: MEIP), an oncolo
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA INITIATES PHASE II CLINICAL TRIAL OF PRACINOSTAT AND VIDAZA IN FRONTLINE MYELODYSPLASTIC
MEI PHARMA INITIATES PHASE II CLINICAL TRIAL OF PRACINOSTAT AND VIDAZA IN FRONTLINE MYELODYSPLASTIC SYNDROME First Patients Dosed in Multicenter, Randomized, Placebo-Controlled Study San Diego June 18, 2013 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA ADDS FORMER YM BIOSCIENCES CEO NICK GLOVER TO BOARD OF DIRECTORS San Diego
MEI PHARMA ADDS FORMER YM BIOSCIENCES CEO NICK GLOVER TO Diego June 11, 2013 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of Nick Glover, Ph.D., to its Board of Directors.
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA ANNOUNCES $15.2 MILLION REGISTERED OFFERING OF COMMON STOCK San Diego
MEI PHARMA ANNOUNCES $15.2 MILLION REGISTERED OFFERING OF COMMON STOCK San Diego April 5, 2013 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today an underwritten registered offering of 2,030,00
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA ADDS CANCER DRUG DEVELOPMENT VETERAN TOM REYNOLDS TO BOARD OF DIRECTORS San Diego
MEI PHARMA ADDS CANCER DRUG DEVELOPMENT VETERAN TOM REYNOLDS TO BOARD OF DIRECTORS San Diego February 11, 2013 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of Thomas C. Re
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA ANNOUNCES RETIREMENT OF CHAIRMAN BRYAN WILLIAMS FROM BOARD OF DIRECTORS AND APPOINTMENT
MEI PHARMA ANNOUNCES RETIREMENT OF CHAIRMAN BRYAN WILLIAMS FROM BOARD OF DIRECTORS AND APPOINTMENT OF CHRISTINE WHITE AS LEAD DIRECTOR San Diego January 30, 2013 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for canc
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA ANNOUNCES CLOSING OF $27.5 MILLION PRIVATE PLACEMENT San Diego
MEI PHARMA ANNOUNCES CLOSING OF $27.5 MILLION PRIVATE PLACEMENT San Diego December 19, 2012 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed its previously announced pri
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA ANNOUNCES $27.5 MILLION PRIVATE PLACEMENT Financing Led by New Institutional Investors V
MEI PHARMA ANNOUNCES $27.5 MILLION PRIVATE PLACEMENT Financing Led by New Institutional Investors Vivo Ventures and New Leaf Venture Partners San Diego November 5, 2012 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies f
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA TO ACQUIRE PRACINOSTAT, A POTENTIAL BEST-IN-CLASS HDAC INHIBITOR Management Team to Host
Exhibit 99.1 Contact: Pete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pdespain@meipharma.com MEI PHARMA TO ACQUIRE PRACINOSTAT, A POTENTIAL BEST-IN-CLASS Management Team to Host Conference Call Today at 5:00 p.m. Eastern Time August
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR ONCOLOGY DRUG CANDID
Contact: Pete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR ONCOLOGY DRUG CANDIDATE ME-344 San Diego March 6, 2012 Marshall Edwa
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS ADDS $2 MILLION IN PRIVATE PLACEMENT San Diego
Contact: Pete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS ADDS $2 MILLION IN PRIVATE PLACEMENT San Diego December 29, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology co
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS ANNOUNCES $2 MILLION PRIVATE PLACEMENT San Diego
Contact: Pete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS ANNOUNCES $2 MILLION PRIVATE PLACEMENT San Diego September 28, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology
Read more →LITSReminder: Marshall Edwards to Host Conference Call on Thursday, September 29 San Diego
Reminder: Marshall Edwards to Host Conference Call on Thursday, September 29 Diego September 27, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, will host a conference call wit
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS ANNOUNCES INITIATION OF PHASE I CLINICAL TRIAL OF LEAD ONCOLOGY DRUG
MARSHALL EDWARDS ANNOUNCES INITIATION OF PHASE I CLINICAL TRIAL OF LEAD ONCOLOGY DRUG CANDIDATE ME-143 San Diego September 8, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, a
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS ADDS FORMER GENENTECH HEAD OF MEDICAL AFFAIRS ROBERT MASS AS CHIEF ME
Contact: Pete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS ADDS FORMER GENENTECH HEAD OF MEDICAL AFFAIRS ROBERT MASS AS CHIEF MEDICAL OFFICER Company Approves Grant Under Nasda
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS ANNOUNCES CLOSING OF ASSET PURCHASE AGREEMENT WITH NOVOGEN San Diego
MARSHALL EDWARDS ANNOUNCES CLOSING OF ASSET PURCHASE AGREEMENT May 10, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the closing of the asset purchase agreeme
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS ANNOUNCES PRIVATE PLACEMENT San Diego
MARSHALL EDWARDS ANNOUNCES PRIVATE PLACEMENT San Diego May 2, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has entered into a definitive agreement w
Read more →LITSPete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS RECEIVES POSITIVE RESPONSE FROM NASDAQ San Diego
Contact: Pete De Spain Sr. Director, Investor Relations & Corporate Communications (858) 792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS RECEIVES POSITIVE RESPONSE FROM NASDAQ San Diego March 16, 2011 Marshall Edwards, Inc. (Nasdaq: MS
Read more →LITSExecution Version VOTING AGREEMENT This VOTING AGREEMENT (this Agreement ), dated as of
This VOTING AGREEMENT (this Agreement ), dated as of December 21, 2010, is entered into by Marshall Edwards, Inc., a Delaware corporation (the Buyer ) and Novogen Limited, a public company limited by shares and incorporated under the laws of New South Wales, Australia (the Stock
Read more →LITSMarshall Edwards to Host Conference Call on
Marshall Edwards to Host Conference Call on September 8, 2010 San Diego August 31, 2010 Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that the Company s management team will hos
Read more →LITSMarshall Edwards, Inc. Contact: Pete De Spain Sr. Director, Investor Relations Corporate Communications 858-792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS APPOINTS ONCOLOGIST CHRISTINE WHITE TO BOARD OF DI
Contact: Pete De Spain Sr. Director, Investor Relations Corporate Communications 858-792-3729 pete.despain@marshalledwardsinc.com MARSHALL EDWARDS APPOINTS ONCOLOGIST CHRISTINE WHITE TO San Diego August 10, 2010 Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology compa
Read more →LITSMarshall Edwards, Inc. CONTACTS: Warren Lancaster 203-966-2556 warren.lancaster@marshalledwardsinc.com David Sheon 202-547-2880 dsheon@WHITECOATstrategies.com MARSHALL EDWARDS ANNOUNCES ADDITIONAL MANAGEMENT CHANGES WITH
CONTACTS: Warren Lancaster 203-966-2556 warren.lancaster@marshalledwardsinc.com David Sheon 202-547-2880 dsheon@WHITECOATstrategies.com MARSHALL EDWARDS ANNOUNCES ADDITIONAL MANAGEMENT CHANGES WITH APPOINTMENT OF NEW CHIEF FINANCIAL San Diego, CA June 17, 2010 Marsha
Read more →LITSMarshall Edwards Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol SYDNEY, AUSTRALIA and SAN DIEGO, CA (
Marshall Edwards Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol SYDNEY, AUSTRALIA and SAN DIEGO, CA (June 1, 2010) Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, annou
Read more →LITSMarshall Edwards, Inc. CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com FOR IMMEDIATE RELEASE MARSHALL EDWARDS, INC.
CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com MARSHALL EDWARDS, INC. RECEIVES NASDAQ NOTICE OF MINIMUM STOCKHOLDERS EQUITY NON-COMPLIANCE NEW CANAAN, CT May 24,
Read more →LITSMarshall Edwards, Inc. CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com MARSHALL EDWARDS APPOINTS CEO AS A NEW DIRECT
CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com 1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com MARSHALL EDWARDS APPOINTS CEO AS A NEW DIRECTOR Sydney, Australia and San Diego, CA May 6, 2010 Marshall Edwards, Inc. (NASD
Read more →LITSMARSHALL EDWARDS, INC. CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com MARSHALL EDWARDS APPOINTS NEW PRESIDENT AND C
1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com MARSHALL EDWARDS APPOINTS NEW PRESIDENT AND CEO Sydney, Australia and San Diego CA April 26, 2010 Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeut
Read more →LITSMarshall Edwards, Inc. CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com FOR IMMEDIATE RELEASE MARSHALL EDWARDS
CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com MARSHALL EDWARDS, INC. RECEIVES NOTICE OF COMPLIANCE WITH NASDAQ CONTINUED LISTING REQUIREMENTS NEW CANAAN, CT April 20, 2
Read more →LITSMarshall Edwards, Inc. Contact: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Seaton 61 2 9878 0088 (Australia) david.saeton@marshalledwardsinc.com MEDIA RELEASE Monday
61 2 9878 0088 (Australia) david.saeton@marshalledwardsinc.com Monday February 8, 2010 Marshall Edwards, Inc. announces resignation of Christopher Naughton from Board of Directors Sydney, Australia February 8, 2010 Marshall Edwards, Inc. (NASDAQ: MSHL) announced that Christo
Read more →LITSMarshall Edwards, Inc. CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 202 547-2880 dsheon@WHITECOATstrategies.com MEDIA RELEASE MARSHALL EDWARDS, INC. APPOINTS ACTING
CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 202 547-2880 dsheon@WHITECOATstrategies.com MARSHALL EDWARDS, INC. APPOINTS ACTING CEO Sydney, Australia and New Canaan, Conn. December 1, 2009 Novogen Limited advises
Read more →LITSMarshall Edwards, Inc. CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com FOR IMMEDIATE RELEASE (New Canaan CT and Sydn
CONTACTS: Warren Lancaster 1-203-966-2556 (USA) warren.lancaster@marshalledwardsinc.com David Sheon 1 202 547-2880 (USA) dsheon@WHITECOATstrategies.com (New Canaan CT and Sydney Australia August 5, 2009) Novogen Limited and Marshall Edwards, Inc. (MSHL) have conclude
Read more →LITSBiotech Analyst Joins Board of Directors of Marshall Edwards, Inc. NEW CANAAN, CT and SYDNEY, AUSTRALIA 03/19/09 Marshall Edwards, Inc. (NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the Board of D
Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc. NEW CANAAN, CT and SYDNEY, AUSTRALIA 03/19/09 Marshall Edwards, Inc. (NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the Board of Directors of the Company. Ms. Cann is an independent resea
Read more →LITSMarshall Edwards, Inc. Announces Resignation of Stephen Breckenridge from Board of Directors and appointment of William Rueckert as Chairman of Audit Committee New Canaan, Connecticut
Marshall Edwards, Inc. Announces Resignation of Stephen Breckenridge from Board of Directors and appointment of William Rueckert as Chairman of Audit Committee New Canaan, Connecticut December 19, 2008 Marshall Edwards, Inc. (NASDAQ: MSHL) announced that Stephen Breckenridge r
Read more →LITSMARSHALL EDWARDS, INC. RAISES $10,000,000 IN PUBLIC OFFERING ( Washington DC; and Sydney Australia
MARSHALL EDWARDS, INC. RAISES $10,000,000 IN PUBLIC OFFERING (Washington DC; and Sydney Australia July 30, 2008) Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that it entered into a Securities Subscription Agreement with Novogen Limited and OppenheimerFunds, Inc. pursu
Read more →LITSexv99w1 OVATURE Phase III trial Update Under U.S. law, a new drug cannot be marketed until it has 1 Ovarian cancer been investigated in clinical trials and approved by the FDA as being safe and effective for the intended
Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/19752003/, based on Nove
Read more →LITSMARSHALL EDWARDS, INC. RAISES $16.4 MILLION IN PRIVATE EQUITY FINANCING (Washington DC; and Sydney Australia
EDWARDS, INC. RAISES $16.4 MILLION IN PRIVATE EQUITY FINANCING (Washington DC; and Sydney Australia August 6, 2007) Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that it entered into definitive agreements for an approximately $16.4 million private placement consistin
Read more →LITSMarshall Edwards, Inc. CONTACT: David Sheon 202 518-6384 (USA) Mr Christopher Naughton (CEO, Marshall Edwards, Inc) 612 8878 6196 (Australia) FOR IMMEDIATE RELEASE MARSHALL EDWARDS, INC. RENEGOTIATES ANNUAL LICENSE PAYME
Marshall Edwards, Inc. MARSHALL EDWARDS, INC. RENEGOTIATES ANNUAL LICENSE PAYMENTS FOR PHENOXODIOL Washington and Sydney, Australia: April 4, 2007 - Marshall Edwards, Inc. (Nasdaq: MSHL) has renegotiated with Novogen Limited (ASX: NRT Nasdaq: NVGN) the timing of the payment of
Read more →LITSMarshall Edwards, Inc. CONTACT: David Sheon - 202 518-6384 (USA) Mr. Christopher Naughton (CEO, Marshall Edwards, Inc) - +612 8878 6196 (Australia) FOR IMMEDIATE RELEASE NEW BOARD APPOINTMENT AT MARSHALL EDWARDS, INC. Sy
Marshall Edwards, Inc. CONTACT: David Sheon - 202 518-6384 (USA) Mr. Christopher Naughton (CEO, Marshall Edwards, Inc) - +612 8878 6196 (Australia) NEW BOARD APPOINTMENT AT MARSHALL EDWARDS, INC. Sydney: March 28, 2007 - Marshall Edwards, Inc is pleased to announce the appo
Read more →LITSChristopher Naughton CEO Marshall Edwards, Inc 612 8877 6196 David Sheon SciWords, LLC 202 518-6321 FOR IMMEDIATE RELEASE Marshall Edwards, Inc ., appoints Professor Bryan Williams as Chai
Contacts: Christopher Naughton CEO Marshall Edwards, Inc 612 8877 6196 David Sheon SciWords, LLC 202 518-6321 Marshall Edwards, Inc ., appoints Professor Bryan Williams as Chairman. Washington DC (November 28 2006): The Board of Directors of Marshall Edwards, Inc.,
Read more →LITSMARSHALL EDWARDS, INC. RAISES A TOTAL OF APPROXIMATELY $18 MILLION IN PRIVATE EQUITY FINANCINGS; ENTERS INTO $15 MILLION EQUITY LINE OF CREDIT (Washington DC; and Sydney Australia
MARSHALL EDWARDS, INC. RAISES A TOTAL OF APPROXIMATELY $18 MILLION IN PRIVATE EQUITY FINANCINGS; ENTERS INTO $15 MILLION EQUITY LINE OF CREDIT (Washington DC; and Sydney Australia July 12, 2006) Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that it entered into a defin
Read more →LITSMARSHALL EDWARDS, INC. RAISES APPROXIMATELY $14 MILLION IN PRIVATE EQUITY FINANCING; (Washington DC; and Sydney Australia
MARSHALL EDWARDS, INC. RAISES APPROXIMATELY $14 MILLION IN PRIVATE EQUITY FINANCING; (Washington DC; and Sydney Australia July 12, 2006) Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that it entered into definitive agreements for an approximately $14 million private p
Read more →LITSASX MEDIA RELEASE 7 JUNE, 2006 NOVOGEN RENEGOTIATES PHENOXODIOL LICENCE PAYMENT Novogen Limited (ASX: Novogen Nasdaq: NVGN) has renegotiated with Marshall Edwards, Inc. (Nasdaq: MSHL) the timing of an $US8 million milest
RENEGOTIATES PHENOXODIOL LICENCE PAYMENT Limited (ASX: Novogen Nasdaq: NVGN) has renegotiated with Marshall Edwards, Inc. MSHL) the timing of an $US8 million milestone licence payment for phenoxodiol payable to Novogen Limited in December 2006, under the terms of the Licence A
Read more →LITSBLAKE DAWSON WALDRON L A W Y E R S Licence Agreement Novogen Research Pty Limited ABN 87 060 202 931 Marshall Edwards Pty Limited ABN 36 099 665 675 CONTENTS 1. INTERPRETATION 1 1.1 Definitions 1 1.2 Rules for interpreti
BLAKE DAWSON WALDRON L A W Y E R S Novogen Research Pty Limited Marshall Edwards Pty Limited 1. INTERPRETATION 1 1.1 Definitions 1 1.2 Rules for interpreting this document 8 1.3 Business Days 9 2. LICENCE 9 2.1 Grant of licence 9
Read more →LITSMarshall Edwards, Inc. CONTACT: David Sheon - 202 518-6384 (USA) Mr Christopher Naughton (CEO, Marshall Edwards, Inc) - 612 8878 6196 (Australia) FOR IMMEDIATE RELEASE APPOINTMENT OF NEW GOVERNOR CREATES BOARD VACANCY AT
Marshall Edwards, Inc. CONTACT: David Sheon - 202 518-6384 (USA) Mr Christopher Naughton (CEO, Marshall Edwards, Inc) - 612 8878 6196 (Australia) APPOINTMENT OF NEW GOVERNOR CREATES BOARD VACANCY AT MARSHALL EDWARDS, INC. Sydney: March 29, 2006 Following the appointment o
Read more →LITSMarshall Edwards, Inc. FDA grants fast track designation for phenoxodiol in oral dosage form for Prostate Cancer (Washington, DC
Marshall Edwards, Inc. FDA grants fast track designation for phenoxodiol in oral dosage form for Prostate Cancer (Washington, DC January 26, 2005) Marshall Edwards, Inc., (Nasdaq: MSHL / LSE AIM: MSH) today announced that the U.S. Food and Drug Administration (FDA) has granted
Read more →Competitive Position
How LITS ranks across every disease it competes inCompetitive Position is a premium feature
See how LITS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial